Faculty Opinions recommendation of Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

2016 ◽  
Author(s):  
Richard Riedel
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Trial ◽  
Open Label Phase ◽  
Phase 1B

scholarly journals Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

The Lancet ◽  
2016 ◽  
Vol 388 (10043) ◽  
pp. 488-497 ◽  
Author(s):  
William D Tap ◽  
Robin L Jones ◽  
Brian A Van Tine ◽  
Bartosz Chmielowski ◽  
Anthony D Elias ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Trial ◽  
Open Label Phase ◽  
Phase 1B

scholarly journals Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

2017 ◽  
Vol 18 (11) ◽  
pp. 1493-1501 ◽  
Author(s):  
Hussein A Tawbi ◽  
Melissa Burgess ◽  
Vanessa Bolejack ◽  
Brian A Van Tine ◽  
Scott M Schuetze ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Bone Sarcoma ◽  
Phase 2 ◽  
Open Label ◽  
Advanced Soft Tissue Sarcoma ◽  
Phase 2 Trial ◽  
Open Label Phase

scholarly journals Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

2013 ◽  
Vol 14 (4) ◽  
pp. 371-382 ◽  
Author(s):  
Gary K Schwartz ◽  
William D Tap ◽  
Li-Xuan Qin ◽  
Michael B Livingston ◽  
Samir D Undevia ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Trial ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document